Janssen Scientific Affairs, LLC - Recruiting 18 years or older. - A Single Arm, Open Label Study to Assess the Pharmacokinetics of Darunavir/Ritonavir and/or Etravirine and Rilpivirine in HIV-1 Infected Pregnant Women.
National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting N/A to 17 years. - Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of GSK1349572, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents.
Dolutegravir (DTG) tablet formulation; DTG oral pediatric granules taken as suspension or granules
Gilead Sciences - Recruiting 18 years or older. - A Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults.
Gilead Sciences - Recruiting 12 years to 17 years. - A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents.
National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older. - A Cohort Observational Study Evaluating Predictors, Incidence and Immunopathogenesis of Immune Reconstitution Syndrome (IRIS) in HIV-1 Infected Patients With CD4 Count Less Than or Equal to 100 Cells/microL Who Are Initiating Antiretroviral Therapy.
Gilead Sciences - Recruiting N/A to 17 years. - A Phase 2/3 Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG)Administered With a Background-Regimen (BR) Containing a Ritonavir-Boosted Protease Inhibitor (PI/r) in HIV-1 Infected, Antiretroviral Treatment-Experienced Pediatric Subjects.
Merck Sharp & Dohme Corp. - Recruiting 18 years or older. - Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients.
KineMed - Recruiting 18 years or older. - Cellular and Molecular Kinetics of Cerebrospinal Fluid (CSF) Using Heavy Water Labeling Method: A Study of Healthy Controls, CNS HIV Infection, Parkinson's Disease and Other Neurodegenerative Diseases.
Deutsche Luft und Raumfahrt - Recruiting 18 years or older. - Incidence, Prevalence, Spectrum of HPV-types, and Viral Load Determination of High-risk Human Papillomavirus Infection of the Oral Cavity in HIV-infected Men Who Have Sex With Men.
Oral swabs for HPV-typing and high-risk HPV-determination
Deutsche Luft und Raumfahrt - Recruiting 18 years or older. - Evaluation of Viral Load Determination and Other Biomarkers of High Risk HPV-Types as a Marker for Progression of Perianal HPV-infections in HIV-positive Men Who Have Sex With Men.
Smear and biopsy testing for HPV-types and viral load
Gilead Sciences - Recruiting 3 Months to 17 years. - A Phase 2/3, Multicenter, Open-label, Multicohort, Two-Part Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co), Administered With Background Regimen (BR) in HIV-1 Infected, Treatment-Experienced, Virologically Suppressed Pediatric Subjects.
Gilead Sciences - Recruiting 12 years to 17 years. - A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents.
Boehringer Ingelheim Pharmaceuticals - Recruiting 18 years to 64 years. - Observational Study Assessing the Safety, Efficacy and Treatment Adherence of Nevirapine Extended Release (Combined With Other Antiretroviral Drugs) in HIV Infected Patients in Daily Clinical Practice.
International AIDS Vaccine Initiative - Recruiting 18 years to 50 years. - A Phase I Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Trial to Evaluate the Safety and Immunogenicity of a Sendai HIV Vaccine SeV-G(NP) Given Intranasally and Ad35-GRIN Administered Intramuscularly in Prime-Boost Regimens in HIV-Uninfected, Healthy Adult Volunteers.
St. James's Hospital, Ireland - Recruiting 18 years or older. - An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-nave, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone.
Medical Research Council - Recruiting N/A to 3 Days. - An Open Randomized Phase I/II Study Evaluating Safety and Immunogenicity of a Candidate HIV-1 Vaccine, MVA.HIVA, Administered to Healthy Infants Born to HIV-1-infected Mothers.
Imperial College London - Recruiting 18 years or older. - A Randomised, Open Label, Prospective Study to Assess Two Different Therapeutic Strategies Following First Treatment Failure in HIV-1 Infected Subjects.
Darunavir, Ritonavir, Truvada; Darunavir, Ritonavir and Etravirine
University of Texas Southwestern Medical Center - Recruiting 18 years or older. - Human Immunodeficiency Virus Acquired Lipodystrophy (HAL) Classification, Measurement, & Fat Response to a Thiazolidinedione (TZD) Challenge in Differing Adult Phenotypic Presentations.
Centers for Disease Control and Prevention - Recruiting 15 years or older. - Preventing Serious Neonatal and Maternal Peripartum Infections in Developing Country Settings With a High Prevalence of HIV Infection: Assessment of the Disease Burden and Evaluation of an Affordable Intervention in Soweto, South Africa.
Chlorhexidine; Birth canal wipe; sterile water external genital wipe